The management of SARS-CoV 2 has not yet been clearly determined and is based on the potential therapeutics evaluated during the SARS-CoV and MERS-CoV epidemics. Although there is currently no antiviral treatment for the treatment of human coronavirus infections, the preclinical results with remdesivir (RDV) are promising. This antiviral is identified as a drug option to be evaluated against COVID-19, based on data on its activity in vitro and in vivo on the coronaviruses MERS-CoV and SARS-CoV. Today it is used to fight coronavirus. It acts on COVID-19 by interfering with key stages in the replication cycle of the virus.